Endocrine resistance in breast cancer - An overview and update

Robert Clarke, John J. Tyson, J. Michael Dixon

Research output: Contribution to journalArticlepeer-review

253 Scopus citations


Tumors that express detectable levels of the product of the ESR1 gene (estrogen receptor-α; ERα) represent the single largest molecular subtype of breast cancer. More women eventually die from ERα+ breast cancer than from either HER2+ disease (almost half of which also express ERα) and/or from triple negative breast cancer (ERα-negative, progesterone receptor-negative, and HER2-negative). Antiestrogens and aromatase inhibitors are largely indistinguishable from each other in their abilities to improve overall survival and almost 50% of ERα+ breast cancers will eventually fail one or more of these endocrine interventions. The precise reasons why these therapies fail in ERα+ breast cancer remain largely unknown. Pharmacogenetic explanations for Tamoxifen resistance are controversial. The role of ERα mutations in endocrine resistance remains unclear. Targeting the growth factors and oncogenes most strongly correlated with endocrine resistance has proven mostly disappointing in their abilities to improve overall survival substantially, particularly in the metastatic setting. Nonetheless, there are new concepts in endocrine resistance that integrate molecular signaling, cellular metabolism, and stress responses including endoplasmic reticulum stress and the unfolded protein response (UPR) that provide novel insights and suggest innovative therapeutic targets. Encouraging evidence that drug combinations with CDK4/CDK6 inhibitors can extend recurrence free survival may yet translate to improvements in overall survival. Whether the improvements seen with immunotherapy in other cancers can be achieved in breast cancer remains to be determined, particularly for ERα+ breast cancers. This review explores the basic mechanisms of resistance to endocrine therapies, concluding with some new insights from systems biology approaches further implicating autophagy and the UPR in detail, and a brief discussion of exciting new avenues and future prospects.

Original languageEnglish (US)
Pages (from-to)220-234
Number of pages15
JournalMolecular and Cellular Endocrinology
StatePublished - Dec 15 2015
Externally publishedYes

Bibliographical note

Funding Information:
This work was funded in part by awards from the US Public Health Service National Cancer Institute U01-CA184902 , U54-CA149147 and P30-CA51008 .

Publisher Copyright:
© 2015 Elsevier Ireland Ltd.


  • Antiestrogens
  • Autophagy
  • Breast cancer
  • Computational biology
  • Endocrine resistance
  • Systems biology
  • Tamoxifen
  • Unfolded protein response


Dive into the research topics of 'Endocrine resistance in breast cancer - An overview and update'. Together they form a unique fingerprint.

Cite this